×
About 9,578 results

ALLMedicine™ Hypertriglyceridemia Center

Research & Reviews  2,311 results

The cluster of differentiation 36 (CD36) rs1761667 polymorphism interacts with dietary ...
https://doi.org/10.1017/S0007114523000570
The British Journal of Nutrition; Yazdanpanah Z, Salehi-Abargouei A et. al.

Mar 18th, 2023 - Several studies have examined the association between CD36 rs1761667 polymorphism with cardiometabolic risk factors and metabolic syndrome (MetS). This study aimed to investigate the interactions between rs1761667 polymorphism and dietary patterns...

Hypertriglyceridemia as a Cause of Continuous Renal Replacement Therapy Circuit Clottin...
https://doi.org/10.1159/000528574
Blood Purification; Abramovitz BW, Oguntuwase E et. al.

Mar 13th, 2023 - Hypertriglyceridemia is a rarely reported cause of early continuous renal replacement therapy (CRRT) circuit clotting. We have identified and will present 11 published cases in the literature where hypertriglyceridemia has led to CRRT circuit clot...

Hypertriglyceridemia is associated with decline of estimated glomerular filtration rate...
https://doi.org/10.1016/j.ejim.2023.02.019
European Journal of Internal Medicine; Pontremoli R, Desideri G et. al.

Mar 12th, 2023 - This analysis investigated the role of hypertriglyceridemia on renal function decline and development of end-stage kidney disease (ESKD) in a real-world clinical setting. A retrospective analysis using administrative databases of 3 Italian Local H...

Strawberry, Blueberry, and Strawberry-Blueberry Blend Beverages Prevent Hepatic Steatos...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002361
International Journal of Environmental Research and Publi... Sotelo-González AM, Reynoso-Camacho R et. al.

Mar 12th, 2023 - There is an increasing interest in developing natural herb-infused functional beverages with health benefits; therefore, in this study, we aimed to evaluate the effect of strawberry, blueberry, and strawberry-blueberry blend decoction-based functi...

Prevalence of anemia and its associated factors among patients with type 2 diabetes mel...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997001
BMC Endocrine Disorders; Hizomi Arani R, Fakhri F et. al.

Mar 10th, 2023 - PURPOSE: This study intended to investigate the prevalence of anemia and its associated factors among patients with type 2 diabetes mellitus (T2DM) in Gorgan, Iran. This cross-sectional study was conducted on 415 (109 men) patients with T2DM refer...

see more →

Guidelines  4 results

Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Pro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019936
Orphanet Journal of Rare Diseases; Mosbah H, Donadille B et. al.

Apr 21st, 2022 - Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the LMNA gene. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole N...

2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in...
https://doi.org/10.1016/j.jacc.2021.06.011
Journal of the American College of Cardiology; Virani SS, Morris PB et. al.

Aug 2nd, 2021 - 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.|2021|Virani SS,Morris PB,Agarwa...

Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985771
Current Oncology (Toronto, Ont.); Blais N, Adam JP et. al.

Jan 4th, 2021 - The use of lorlatinib, an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive metastatic non-small cell lung cancer, is associated with dyslipidemia in over 80% of patients. Clinical trial protocols for the management of l...

Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.
https://doi.org/10.1016/j.maturitas.2020.03.007
Maturitas Anagnostis P, Bitzer J et. al.

Mar 27th, 2020 - Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein choles...

see more →

Drugs  961 results see all →

Clinicaltrials.gov  277 results

Fenofibrate in Ulcerative Colitis
https://clinicaltrials.gov/ct2/show/NCT05753267

Mar 9th, 2023 - Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa, however the exact underlying mechanisms of UC remain poorly understood. UC is strongly dependent on cellu...

A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia
https://clinicaltrials.gov/ct2/show/NCT05609825

Mar 6th, 2023 - The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also as...

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
https://clinicaltrials.gov/ct2/show/NCT01120249

Mar 2nd, 2023 - OBJECTIVES: Primary to compare recurrence-free survival in renal carcinoma patients randomly assigned to 54 weeks of everolimus versus 54 weeks of placebo after nephrectomy or partial nephrectomy. Secondary To compare the overall survival of patie...

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
https://clinicaltrials.gov/ct2/show/NCT05610280

Mar 1st, 2023 - This is a Phase 3, multi-center, placebo-controlled study of up to 1312 participants with hypertriglyceridemia and atherosclerotic cardiovascular disease. The study consists of 3 periods: 1) Screening Period: Week -8 to Week -1 (up to 8 weeks); 2)...

The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk
https://clinicaltrials.gov/ct2/show/NCT04562467

Mar 1st, 2023 - The development and natural history of atherothrombosis involves the pathophysiological interplay between inflammation, dyslipidemia, oxidative stress and endothelial dysfunction. Unregulated, these processes culminate in endothelial dysfunction, ...

see more →

News  276 results

Oral Antiviral Matches Paxlovid in High-Risk COVID
https://www.medpagetoday.com/infectiousdisease/covid19/102487

Jan 3rd, 2023 - An oral remdesivir analogue (VV116) was just as good as nirmatrelvir-ritonavir (Paxlovid) for the treatment of mild-to-moderate COVID-19 in adults at risk for severe disease, and may be safer, results of a phase III trial from China suggested. Sus...

Metabolic syndrome may promote gout in young men
https://www.mdedge.com/rheumatology/article/260163/gout/metabolic-syndrome-may-promote-gout-young-men
Heidi Splete

Dec 15th, 2022 - Metabolic syndrome is associated with a significantly increased risk for gout in young men, but the risk can be mitigated by improvement in individual components of the syndrome, based on data from a pair of population-based studies totaling more.

Triglyceride-lowering fails to show CV benefit in large fibrate trial
https://www.mdedge.com/cardiology/article/259219/lipid-disorders/triglyceride-lowering-fails-show-cv-benefit-large-fibrate
Ted Bosworth

Nov 5th, 2022 - CHICAGO – Despite a 25% reduction in triglycerides (TGs) along with similar reductions in very-low-density lipoprotein (VLDL), and remnant cholesterol, a novel agent failed to provide any protection in a multinational trial against a composite end.

Triglyceride Lowering Fails to Show CV Benefit in Large Fibrate Trial
https://www.medscape.com/viewarticle/983610

Nov 5th, 2022 - Despite a 25% reduction in triglycerides (TGs) along with similar reductions in very-low-density lipoprotein (VLDL), and remnant cholesterol, a novel agent failed to provide any protection in a multinational trial against a composite endpoint of m...

Pyrotinib Plus Trastuzumab/Docetaxel Prolongs PFS in HER2+ Metastatic Breast Cancer
https://www.onclive.com/view/pyrotinib-plus-trastuzumab-docetaxel-prolongs-pfs-in-her2-metastatic-breast-cancer

Oct 14th, 2022 - The addition of pyrotinib to trastuzumab (Herceptin) and docetaxel significantly improved progression-free survival (PFS) vs trastuzumab/docetaxel alone in patients with HER2-positive metastatic breast cancer, according to data from the phase 3 PH...

see more →

Patient Education  2 results see all →